Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines for the treatment of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. Its products include injections to treat macular edema, moderate-to-severe atopic dermatitis, heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, rheumatoid arthritis. The company also offers injections to treat cryopyrin-associated periodic syndromes and metastatic colorectal cancer. In addition, it develops a trap-based clinical product for the treatment of neovascular glaucoma, and antibody-based clinical programs.
Type | Public | |
Founded | 1988 | |
HQ | Tarrytown, NY, US | Map |
Website | regeneron.com | |
Employee Ratings | More | |
Overall Culture | B- | More |
USD | |
---|---|
Revenue (FY, 2021) | 16.1b |
Gross profit (FY, 2021) | 13.6b |
Gross profit margin (FY, 2021), % | 84.8% |
Net income (FY, 2021) | 8.1b |
EBIT (FY, 2021) | 8.9b |
Market capitalization (13-May-2022) | 69.4b |
Closing stock price (13-May-2022) | 645.5 |
Cash (31-Dec-2021) | 2.9b |
EV | 69.2b |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|
Net Income | 461.1m | 654.2m | 1.3b | 624.6m | 1.5b | 2.4b | 1.1b | 4.2b | 5.8b |
Depreciation and Amortization | 51.0m | 103.1m | 156.0m | 56.1m | 114.9m | 174.2m | 67.4m | 138.5m | 211.7m |
Inventories | (58.6m) | (168.2m) | (227.2m) | (70.8m) | (233.4m) | (402.4m) | (252.8m) | (221.5m) | (330.6m) |
Accounts Payable | (19.6m) | 110.3m | 119.9m | (85.2m) | 20.9m | 80.8m | (34.7m) | 423.7m | 500.4m |
USD | FY, 2018 |
---|---|
Revenue/Employee | 906.9k |
Company Name | Date | Deal Size |
---|---|---|
Eastside Campus Holdings LLC | ||
Loop Road Holdings LLC | ||
Old Saw Mill Holdings LLC | ||
OSMR Holdings | ||
Regeneron Assurance, Inc. | ||
Regeneron Atlantic Holdings | ||
Regeneron Belgium BV | ||
Regeneron Canada Company | ||
Regeneron Capital International B.V. | ||
Regeneron Genetics Center LLC |
Regeneron Pharmaceuticals revenue breakdown by business segment: 65.5% from Product Sales, 27.9% from Sanofi and Bayer Collaboration and 6.6% from Other
Regeneron Pharmaceuticals has 31.4k Twitter Followers. The number of followers has increased 0.1% month over month and increased 0.6% quarter over quarter
4.8k
Tweets
301
Following
31.4k
Followers
21
Tweets last 30 days
4.3
Avg. likes per Tweet
100%
Tweets with engagement
B-
78/100
A
84/100
A-
85/100
When was Regeneron Pharmaceuticals founded?
Regeneron Pharmaceuticals was founded in 1988.
Who are Regeneron Pharmaceuticals key executives?
Regeneron Pharmaceuticals's key executives are Leonard S. Schleifer, Elizabeth Green and Daniel Van Plew.
How many employees does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals has 10,368 employees.
What is Regeneron Pharmaceuticals revenue?
Latest Regeneron Pharmaceuticals annual revenue is $16.1 b.
What is Regeneron Pharmaceuticals revenue per employee?
Latest Regeneron Pharmaceuticals revenue per employee is $1.6 m.
Who are Regeneron Pharmaceuticals competitors?
Competitors of Regeneron Pharmaceuticals include Intersect ENT, Catalent and Bristol-Myers Squibb.
Where is Regeneron Pharmaceuticals headquarters?
Regeneron Pharmaceuticals headquarters is located at 777 Old Saw Mill River Rd, Tarrytown.
Where are Regeneron Pharmaceuticals offices?
Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Sleepy Hollow and in 4 other locations.
How many offices does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals has 8 offices.
Receive alerts for 300+ data fields across thousands of companies